The identification of ERKT188-phosphorylation as a maladaptive trigger of cardiac hypertrophy and heart failure initiated the search for a differential targeting strategy for these central kinases ERK1/2 that are involved in many physiological and pathological processes. Here, MAPK3 is linked to cardiac hypertrophy.